PDF Version Printer-Friendly Version
"Dramatic" finding from a casual chat
It's not often that a casual chat leads to a research project with important implications. But at DMS, at least one study began that way.
Microbiologist George O'Toole, Ph.D., explains that the project—on biofilm infections associated with catheters—grew out of a conversation between Robert Shanks, Ph.D., a postdoctoral fellow in microbiology, and DHMC nephrologist Martha Graber, M.D. And that conversation was stimulated by a chat Graber had had with ophthalmologist Michael Zegans, M.D., about biofilm-related eye infections. As Graber listened, she wondered if some of the Staphylococcus aureus infections she was seeing in the dialysis unit might be biofilm related. Biofilms, which are bacteria in communities rather than in free-swimming or planktonic form, are more resistant to antibiotics.
Later, Graber had lunch with Shanks and other biofilm researchers. And that led to a collaboration with O'Toole, Shanks, and others to investigate whether heparin, an anticoagulant commonly used in dialysis procedures, has an impact on the ability of S. aureus to form biofilms.
"The answer to that question is most definitely yes," O'Toole says. The finding that heparin stimulates the formation of
bacterial biofilms was reported in the journal Infection and Immunity in 2005. A follow- up study published this year in Nephrology Dialysis Transplantation reported that sodium citrate—an anticoagulant used widely in Europe, but not in the U.S., to prevent clotting in catheters between uses—can inhibit biofilm formation.
Patients with failing kidneys must undergo dialysis several times a week. They are connected to a machine via a catheter placed in a large neck vein or via a fistula, a surgically created connection between an artery and vein in the arm. The machine removes, purifies, and
returns blood to the patient. Fistulas are less likely to become infected but cannot be used until the surgery site heals.
There are 400,000 vascular catheter infections a year in the U.S., caused mostly by S. aureus. "Bugs get in through the hole where the blood goes," Graber says. "It's the Achilles' heel of catheters." And so is heparin. Although it's effective at preventing clotting in catheters, it can leave patients vulnerable to hard-totreat biofilm infections.
Staph: In order for biofilms to form, "you need cells attaching to a surface and cells attaching to each other," O'Toole explains. "Heparin seems to stimulate the ability of staph to bind to itself." Shanks, who is now on the faculty at the University of Pittsburgh, is studying the mechanism by which heparin does this. And at DMS, O'Toole's lab is investigating how sodium citrate works and is testing alternatives. Sodium citrate is not widely used in dialysis in the U.S. because of fear of accidental infusion of highly concentrated forms. DHMC uses heparin.
The heparin-biofilm association was unknown until the Dartmouth papers. "This was such a clear finding—it was so dramatic," says Graber. "I was incredibly surprised."
If you'd like to offer feedback about this article, we'd welcome getting your comments at DartMed@Dartmouth.edu.
This article may not be reproduced or reposted without permission. To inquire about permission, contact DartMed@Dartmouth.edu.